Unprecedented Results at 2 Years

MAJESTIC Clinical Trial

2-year Data

  • 91.3% Freedom from TLR
  • 91% patients with no or minimal claudication
  • 0 stent fractures at 2 years

Objective

To evaluate the performance of the Eluvia Drug-Eluting Vascular Stent System in the treatment of superficial femoral (SFA) and/or proximal popliteal artery (PPA) lesions.